Yu Y, et al. - Among the esthesioneuroblastoma patients treated with surgical resection and postoperative radiation, authors aimed to quantify the rate of late intracranial recurrences. A substantial and a unique risk of long-term dural-based relapse was noted in the esthesioneuroblastoma patients presenting with intracranial extension.

Methods

• Experts conducted a retrospective review.
• They reviewed all the patients who were given definitive-intent therapy for esthesioneuroblastoma between March 1995 and September 2015.
• Based on radiologic, operative, and pathologic findings, presenting disease extent was categorized.
• An evaluation was performed of the between-group survival differences with the use of Kaplan-Meier method and log-rank test.
• Using Cox proportional hazards model multivariate analyses were performed.

Results

• It was revealed that 53% patients (20 of 38) presented with intracranial extension, among 38 patients initially treated at the institution.
• In the median follow-up of 90 months (range, 6-199), recurrence was noted in 37% cases (14 of 38); 5- and 8-year disease-free survival rates were found to be 69% and 54%; and the overall survival rates were seen to be 81% and 72%, respectively.
• Dura was the most commonly involved site of relapse (8), followed by local (6), regional (5), and distant extracranial (3) sites; and 5 patients reported ≥ two categories of failure.
• Data revealed that the 8-year dural disease-free survival was 57% vs 90% (P=0.017) and 0% vs 87% (P < 0.0001), with and without intracranial extension and subtotal resection, respectively.
• Out of 6 patients treated at recurrence, 5 (83%) reported dural-based failure which indicated that, among all 44 patients, 13 (65%) of 20 recurrences involved the dura.
• The median survival time was 42 months (range, 12-125) after dural recurrence.
• Findings illustrated that salvage treatments were effective in rare cases of isolated low-volume recurrence.